The notices it replaced
- Reissues: RFA-HL-20-006 Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38) (Clinical Trial Not Allowed)
Replaced by RFA-HL-27-010.
Who won it before
21 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,162,444 in first-year total cost, median $107,752.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-I (M1)]8
- Special Emphasis Panel[ZHL1 CSR-I (M3)]4
- Transition to Independence Study Section (I)[NCI-I]3
- Special Emphasis Panel[ZHL1 CSR-S (M1)]2
- Special Emphasis Panel[ZHL1 CSR-Z (M2)]2
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO6
- DUKE UNIVERSITY5
- EMORY UNIVERSITY2
- UNIVERSITY OF CALIFORNIA LOS ANGELES2
- BETH ISRAEL DEACONESS MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | The Role of Rheology and Transfusion on Microvascular Thrombosis in Sepsis1K38HL181374-01 | IFFRIG, ELIZABETH M | EMORY UNIVERSITY, GA | $110,635 | ZHL1 |
| 2025 | Epithelial cell mediated fibroblast activation through CTHRC1-TGFb signaling in fibrotic lung diseases1K38HL180998-01 | KHATRI, AADITYA | DUKE UNIVERSITY, NC | $107,752 | ZHL1 |
| 2025 | Improving integration of treatment burden information in primary care for older adults with multiple chronic conditions1K38AG094915-01 | ZHANG, AUDREY DEE | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $107,330 | ZHL1 |
| 2025 | The Role of Developmental Dysanapsis in Lung Development Throughout the Lifespan in Experimental Bronchopulmonary Dysplasia1K38HL180910-01 | MCGINN, ELIZABETH | UNIVERSITY OF COLORADO DENVER, CO | $106,391 | ZHL1 |
| 2025 | Predictive Markers of Response to and Treatment Effects of Motixafortide, Cemiplimab, Gemcitabine and Nab-Paclitaxel in Treatment Naïve Metastatic Pancreatic Cancer1K38CA304069-01 | MAY, MICHAEL STEVENSON | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $1 | NCI |
| 2024 | Control of adipose immune-stromal niche topography in obesity1K38HL175025-01 | BALCEREK, JOANNA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $115,949 | ZHL1 |
| 2024 | The Lipofibroblast to Myofibroblast Transition in Systemic Sclerosis1K38HL175027-01 | YOUNG, ARISSA C | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $110,959 | ZHL1 |
| 2024 | Age-Related Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Exercise Responsiveness1K38HL175026-01 | REGAN, JESSICA ANN | DUKE UNIVERSITY, NC | $104,933 | ZHL1 |
| 2024 | B Cell-Fibroblast Crosstalk Promotes Chronic GVHD of the Lung1K38AI185078-01 | BRACKEN, SONALI JAGDISH | DUKE UNIVERSITY, NC | $104,435 | AITC |
| 2024 | Metabolic regulation of oxidative phosphorylation in pediatric AML relapse1K38CA282963-01A1 | ZACHMAN, DEREK | DUKE UNIVERSITY, NC | $103,853 | NCI |
| 2024 | Cell-Free DNA Methylation Patterns as a Biomarker for Tumor Biology and Clinical Outcomes for Glioblastoma Patients1K38CA292995-01 | VAIOS, EUGENE | DUKE UNIVERSITY, NC | $100,586 | NCI |
| 2024 | The impact of diet on granulopoiesis, neutrophil function, and sickle cell disease pathology1K38HL174893-01 | MACK, ETHAN ANDREW | UNIVERSITY OF PENNSYLVANIA, PA | $89,640 | ZHL1 |
| 2023 | Investigating the Genotype-Phenotype Relationships that Underlie Congenital Disorders with Cardiovascular Symptoms through Population-scale Analyses1K38HL164956-01A1 | BLAIR, DAVID RANDALL | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $109,752 | ZHL1 |
| 2023 | Improving the Identification of Opioid-Associated Out-of-Hospital Cardiac Arrest1K38HL165363-01A1 | DILLON, DAVID G | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $106,164 | ZHL1 |
| 2023 | Identifying genetic drivers of circulating metabolites associated with cardiac risk in pediatric chronic kidney disease1K38HL169660-01 | LEE, ARTHUR | CHILDREN'S HOSP OF PHILADELPHIA, PA | $105,867 | ZHL1 |
| 2022 | Using Machine Learning and Patient-Reported Outcomes to Identify Unnecessary Hospitalizations1K38HL164955-01 · under RFA-HL-20-006 | LEUCHTER, RICHARD K | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $111,866 | ZHL1 |
| 2022 | Control of ribosomal function in cells of the hematopoietic system1K38HL165490-01 · under RFA-HL-20-006 | LEVINE, ANDREW | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $111,089 | ZHL1 |
| 2021 | Deep learning tools for the automated analysis of hematopathology whole slide images and the development of prognostic algorithms for hematopoietic stem cell transplant recipients1K38HL159128-01 · under RFA-HL-20-006 | GOLDGOF, GREGORY MARK | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $119,318 | ZHL1 |
| 2021 | Systems Biology Approach to SARS-CoV-2 Infection in Individuals with known COVID-19 Contacts: A Prospective Cohort Study1K38AI163480-01 · under RFA-HL-20-006 | SCANLON, NICHOLAS | EMORY UNIVERSITY, GA | $108,886 | ZAI1 |
| 2020 | Host-parasite lipid metabolism in Trypanosoma cruzi-infected cardiac myocytes1K38HL154203-01 · under RFA-HL-20-006 | WHITMAN, JEFFREY DOMINICK | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $113,519 | ZHL1 |
| 2020 | The Role of PPARgamma in Th2 cells and Obesity-Associated Asthma.1K38HL154202-01 · under RFA-HL-20-006 | BAPAT, SAGAR PRADEEP | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $113,519 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.1.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.